12:00 AM
Jul 28, 2014
 |  BioCentury  |  Finance

Gut reaction

Synlogic using $29.4M series A to fine-tune bacterial drug delivery
Gut reaction

Synlogic Inc. is using its $29.4 million series A round to develop engineered microbes that could enable more fine-tuned delivery of therapeutic proteins than other bacterial delivery platforms, as well as have a unique ability to process toxins.

Last week, the company raised an undisclosed amount in the tranched round co-led by existing investor Atlas Venture and new investor New...

Read the full 300 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >